Adequacy of antimicrobial treatment and outcome of staphylococcus aureus bacteremia in 9 western European countries

Clinical Infectious Diseases

Volumn 49, Issue 7, 2009, Pages 997-1005

  Ammerlaan, Heidi ^a,b   Seifert, Harald ^e   Harbarth, Stephan ^f   Brun Buisson, Christian ^g   Torres, Antoni ^h   Antonelli, Massimo ⁱ   Kluytmans, Jan ^c,d   Bonten, Marc ^a,b  

^a Department of Medical Microbiology ^*  (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c AMPHIA HOSPITAL   (Netherlands)

^d VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^e UNIVERSITY OF COLOGNE   (Germany)

^f GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^g HENRI MONDOR HOSPITAL   (France)

^h UNIVERSITY OF BARCELONA   (Spain)

ⁱ CATHOLIC UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; ANTIBIOTIC AGENT; BETA LACTAM; CIPROFLOXACIN; GENTAMICIN; OXACILLIN; PENICILLIN G; PIPERACILLIN PLUS TAZOBACTAM; TRIMETHOPRIM;

ADULT; AGED; ANTIBIOTIC RESISTANCE; ARTICLE; COMORBIDITY; CONTROLLED STUDY; FEMALE; HOSPITALIZATION; HUMAN; IN VITRO STUDY; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MORTALITY; PRIORITY JOURNAL; SEPSIS; SEPTIC SHOCK; STAPHYLOCOCCAL BACTEREMIA; TREATMENT OUTCOME; TREATMENT RESPONSE; WESTERN EUROPE;

AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BACTEREMIA; COHORT STUDIES; EUROPE; FEMALE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; RETROSPECTIVE STUDIES; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; TREATMENT OUTCOME;

EID: 70349895547     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/605555     Document Type: Article

References (28)

1. van der Mee-Marquet NA, Domelier AS, Girard N, Quentin R. Epidemiology and typing of Staphylococcus aureus strains isolated from bloodstream infections. J Clin Microbiol 2004; 42:5650-5657
2. Diekema DJ, Beekmann SE, Chapin KC, Morel KA, Munson E, Doern GV. Epidemiology and outcome of nosocomial and community-onset bloodstream infection. J Clin Microbiol 2003; 41:3655-3660 (Pubitemid 36994698)
3. Noskin GA, Rubin RJ, Schentag JJ, et al. The burden of Staphylococcus aureus infections on hospitals in the United States: an analysis of the 2000 and 2001 Nationwide Inpatient Sample Database. Arch Intern Med 2005; 165:1756-1761
4. Steinberg JP, Clark CC, Hackman BO. Nosocomial and communityacquired Staphylococcus aureus bacteremias from 1980 to 1993: impact of intravascular devices and methicillin resistance. Clin Infect Dis 1996; 23:255-259
5. Banerjee SN, Emori TG, Culver DH, et al. Secular trends in nosocomial primary bloodstream infections in the United States, 1980-1989. National Nosocomial Infections Surveillance System. Am J Med 1991; 91: 86S-9S.
6. Lyytikainen O, Ruotsalainen E, Jarvinen A, Valtonen V, Ruutu P. Trends and outcome of nosocomial and community-acquired bloodstream infections due to Staphylococcus aureus in Finland, 1995-2001. Eur J Clin Microbiol Infect Dis 2005; 24:399-1104
7. European Antimicrobial Resistance Surviellance System. Available at: http://www.rivm.nl/earss/. Accessed 6 August 2009.
8. Harbarth S, Rutschmann O, Sudre P, Pittet D. Impact of methicillin resistance on the outcome of patients with bacteremia caused by Staphylococcus aureus. Arch Intern Med 1998; 158:182-189
9. Wertheim HF, Vos MC, Ott A, et al. Risk and outcome of nosocomial Staphylococcus aureus bacteraemia in nasal carriers versus non-carriers. Lancet 2004; 364:703-705
10. Laupland KB, Church DL, Mucenski M, Sutherland LR, Davies HD. Population-based study of the epidemiology of and the risk factors for invasive Staphylococcus aureus infections. J Infect Dis 2003; 187:1452-1459
11. Soriano A, Martinez JA, Mensa J, et al. Pathogenic significance of methicillin resistance for patients with Staphylococcus aureus bacteremia. Clin Infect Dis 2000; 30:368-373
12. Kim SH, Park WB, Lee CS, et al. Outcome of inappropriate empirical antibiotic therapy in patients with Staphylococcus aureus bacteraemia: analytical strategy using propensity scores. Clin Microbiol Infect 2006; 12:13-21.
13. Valles J, Rello J, Ochagavia A, Garnacho J, Alcala MA. Communityacquired bloodstream infection in critically ill adult patients: impact of shock and inappropriate antibiotic therapy on survival. Chest 2003; 123: 1615-1624 (Pubitemid 36549784)
14. Gemmell CG, Edwards DI, Fraise AP, Gould FK, Ridgway GL, Warren RE. Guidelines for the prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in the UK. J Antimicrob Chemother 2006; 57:589-608.
15. Lodise TP, McKinnon PS, Swiderski L, Rybak MJ. Outcomes analysis of delayed antibiotic treatment for hospital-acquired Staphylococcus aureus bacteremia. Clin Infect Dis 2003; 36:1418-1423
16. Lodise TP, McKinnon PS. Clinical and economic impact of methicillin resistance in patients with Staphylococcus aureus bacteremia. Diagn Microbiol Infect Dis 2005; 52:113-122
17. Chang FY, MacDonald BB, Peacock JE, Jr., et al. A prospective multicenter study of Staphylococcus aureus bacteremia: incidence of endocarditis, risk factors for mortality, and clinical impact of methicillin resistance. Medicine (Baltimore) 2003; 82:322-332
18. Laupland KB, Gregson DB, Zygun DA, Doig CJ, Mortis G, Church DL. Severe bloodstream infections: a population-based assessment. Crit Care Med 2004; 32:992-997 (Pubitemid 38471521)
19. Schramm GE, Johnson JA, Doherty JA, Micek ST, Kollef MH. Methicillin-resistant Staphylococcus aureus sterile-site infection: the importance of appropriate initial antimicrobial treatment. Crit Care Med 2006; 34:2069-2074
20. Lin MY, Weinstein RA, Hota B. Delay of active antimicrobial therapy and mortality among patients with bacteremia: impact of severe neutropenia. Antimicrob Agents Chemother 2008; 52:3188-3194
21. Kim SH, Park WB, Lee KD, et al. Outcome of inappropriate initial antimicrobial treatment in patients with methicillin-resistant Staphylococcus aureus bacteraemia. J Antimicrob Chemother 2004; 54:489-497
22. Scarsi KK, Feinglass JM, Scheetz MH, Postelnick MJ, Bolon MK, Noskin GA. Impact of inactive empiric antimicrobial therapy on inpatient mortality and length of stay. Antimicrob Agents Chemother 2006; 50: 3355-3360
23. McGregor JC, Rich SE, Harris AD, et al. A systematic review of the methods used to assess the association between appropriate antibiotic therapy and mortality in bacteremic patients. Clin Infect Dis 2007; 45: 329-337
24. Harbarth S, Nobre V, Pittet D. Does antibiotic selection impact patient outcome? Clin Infect Dis 2007; 44:87-93.
25. Schneeweiss S, Wang PS, Avorn J, Glynn RJ. Improved comorbidity adjustment for predicting mortality in Medicare populations. Health Serv Res 2003; 38:1103-1120 (Pubitemid 37048302)
26. Levy MM, Fink MP, Marshall JC, et al. 2001 SCCM/ESICM/ACCP/ ATS/SIS International Sepsis Definitions Conference. Crit Care Med 2003; 31:1250-1256 (Pubitemid 36444440)
27. Guignard B, Entenza JM, Moreillon P. Beta-lactams against methicillinresistant Staphylococcus aureus. Curr Opin Pharmacol 2005; 5:479-489
28. Lodise TP Jr, McKinnon PS, Levine DP, Rybak MJ. Impact of empiricaltherapy selection on outcomes of intravenous drug users with infective endocarditis caused by methicillin-susceptible Staphylococcus aureus. Antimicrob Agents Chemother 2007; 51:3731-3733